BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization

– PDUFA target action date set for September 9, 2023 – NDA submission based on GENESIS Phase 3 trial data that met all primary and secondary endpoints with a high level of statistical significance – Company advancing preparations for robust commercial launch TEL AVIV, Israel, Nov. 10,…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.